Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

An aqueous composition includes water and a cationic polymeric resin having at least one reactive aldehyde group and formed from the reaction of glyoxal and a polymer. The polymer comprises at least one acrylamide repeating unit and at least one cationic repeating unit wherein a number of reactive aldehyde equivalents divided by a number of equivalents of residual glyoxal based on the total weight of the polymer is greater than about 1.2, wherein prior to reaction the polymer has greater than about 50 mole % acrylamide repeat units and from about 2 to about 30 mole % cationic repeating units, wherein greater than about 5 mole % of the acrylamide repeating units are converted to reactive aldehyde groups in the cationic polymer resin; and wherein the composition exhibits a viscosity gain of less than about 200%.

An aqueous composition includes water and a cationic polymeric resin having at least one reactive aldehyde group and formed from the reaction of glyoxal and a polymer. The polymer comprises at least one acrylamide repeating unit and at least one cationic repeating unit wherein a number of reactive aldehyde equivalents divided by a number of equivalents of residual glyoxal based on the total weight of the polymer is greater than about 1.2, wherein prior to reaction the polymer has greater than about 50 mole % acrylamide repeat units and from about 2 to about 30 mole % cationic repeating units, wherein greater than about 5 mole % of the acrylamide repeating units are converted to reactive aldehyde groups in the cationic polymer resin; and wherein the composition exhibits a viscosity gain of less than about 200%.

To provide a hydrophilizing surface treatment liquid suppressing the deterioration over time of the effect of a surface treatment even when a surface-treated article is exposed to a variety of chemicals and a hydrophilizing treatment method in which the hydrophilizing surface treatment liquid is used. In a hydrophilizing surface treatment liquid including a polymerizable compound having an ethylenic unsaturated double bond (A), a polymerization initiator (B) and a solvent (S), a hydrophilic polymerizable compound (A1), an adhesive polymerizable compound (A2), an acidic polymerizable compound (A3a) and/or a basic polymerizable compound (A3b) are used as the polymerizable compound (A), and an aqueous solution including the polymerizable compound (A) at a concentration of 10% by mass has a pH at 23° C. of 6.5 or more and 7.5 or less.

To provide a hydrophilizing surface treatment liquid suppressing the deterioration over time of the effect of a surface treatment even when a surface-treated article is exposed to a variety of chemicals and a hydrophilizing treatment method in which the hydrophilizing surface treatment liquid is used. In a hydrophilizing surface treatment liquid including a polymerizable compound having an ethylenic unsaturated double bond (A), a polymerization initiator (B) and a solvent (S), a hydrophilic polymerizable compound (A1), an adhesive polymerizable compound (A2), an acidic polymerizable compound (A3a) and/or a basic polymerizable compound (A3b) are used as the polymerizable compound (A), and an aqueous solution including the polymerizable compound (A) at a concentration of 10% by mass has a pH at 23° C. of 6.5 or more and 7.5 or less.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

An object of the present invention is to provide a diverting agent that exhibits sufficient filling properties against a fracture in a well because of swelling without completely dissolution for a certain period of time (about 30 minutes to 5 hours), and that quickly dissolves and be removed even at a low temperature of 40° C. to 60° C. after a certain period of time has passed. The present invention relates to a diverting agent containing a modified polyvinyl alcohol-based resin.